<DOC>
	<DOC>NCT02638948</DOC>
	<brief_summary>The purpose of this study is to determine whether the study drug, BMS-986142, is safe and effective in treating moderate to severe rheumatoid arthritis in subjects with an inadequate response to methotrexate or methotrexate and up to 2 tumour necrosis factor (TNF) Inhibitors. Patients who qualify will be randomized to either one of 3 doses of BMS-986142 or placebo in 1:1:1:1 randomization for 12 weeks. Disease activity and safety will be assessed over the course of the study.</brief_summary>
	<brief_title>Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Male and female age 18 and above Diagnosed with active rheumatoid arthritis (RA) by standard criteria at least 16 weeks before screening, have functional ACR class IIII Have an inadequate response to methotrexate In addition to an inadequate response to methotrexate have an inadequate response or intolerance to 1 but not more than 2 TNF inhibitors Have a minimum of 6 swollen and 6 tender joints (from 66/68 joint count) Have hsCRP of ≥ 0.8 mg/dL (8mg/L) [by central laboratory values] or an ESR ≥ 28 mm/hr Willing to use effective birth control for the entire length of the study Diagnosed with juvenile Rheumatoid Arthritis Have been treated with other biologic treatment than a TNF inhibitor Active systemic bacterial, viral or fungal infection or evidence of prior or current Hepatitis B or C infection or HIV infection, latent bacterial, viral or fungal infections Have been treated with Intramuscular or Intraarticular glucocorticosteroids within 4 weeks of randomization Taking Oral steroids at dose above 10 mg/day of prednisone (or prednisone equivalents) Have other autoimmune disease other than RA like lupus, multiple sclerosis Have significant concurrent medical condition at the time of screening or baseline visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>